Why the study?
Although short-term trials showed nicorandil was not inferior to standard antianginal agents, mixed efficacy versus placebo, unconfirmed cardiovascular event reduction, and ulceration risks have questioned its positioning relative to first-line drugs.
Does nicorandil provide superior or equivalent antianginal efficacy and cardiovascular event reduction compared to first-line agents or placebo in patients with chronic coronary syndromes?
Does nicorandil provide superior or equivalent antianginal efficacy and cardiovascular event reduction compared to first-line agents or placebo in patients with chronic coronary syndromes?
Nicorandil remains a lower-priority antianginal drug due to inconsistent efficacy compared to placebo, lack of modern prognostic data, and risk of gastrointestinal ulcerations.
Answers are grounded in this paper and cite their sources.
Nicorandil lacks proven antianginal benefit over placebo; challenges routine first-line use and warrants confirmatory long-term RCTs.
According to the results of several short-term randomized controlled trials (RCTs), nicorandil is not inferior in its antianginal efficacy to beta-blockers (BB), calcium channel blockers (CCB) and long-acting nitrates (LAN). At the same time, in some short-term RCTs, as well as in the long-term RCT IONA (2002), it was shown that antianginal efficacy of nicorandil as monotherapy or in combination with other antianginal drugs did not differ from placebo. Ability of nicorandil to reduce the risk of adverse cardiovascular events, demonstrated in the RCT IONA, requires confirmation in a long-term trial with a stronger primary endpoint and concomitant treatment that would meet the current guidelines for the management of patients with chronic coronary syndromes. In this regard, and also taking into account the proven ability of nicorandil to cause gastrointestinal ulcerations, European experts currently consider nicorandil as a drug that is inferior in priority of choice to the first-line antianginal drugs (BB, CCB) and, in some cases, to the second-line drugs (LAN, ivabradine, ranolazine, trimetazidine).
No takes yet. Share an insight, caveat, or question.
Бельдиев et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: